Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.

Abstract

Glioblastoma is the most malignant primary brain tumor with a median survival of 15 months. Temozolomide (TMZ) is the standard of care for these patients. Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas. In the present study, we found that combination treatment in glioma cells with TMZ and DFP significantly reduced cell viability, produced cell cycle arrest at G2/M phase, and enhanced apoptosis. TMZ and DFP might be a potent new combination treatment for glioblastoma.

• Authors: George A Alexiou, Paraskevi Gerogianni, Evrysthenis Vartholomatos, Athanasios P Kyritsis
• Journal: Cancer investigation (Cancer Invest) Vol. 34 Issue 10 Pg. 489-495 (Nov 25 2016) ISSN: 1532-4192 [Electronic] England
• PMID: 27768402 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents, Alkylating
• Iron Chelating Agents
• Pyridones
• Deferiprone
• Dacarbazine
• Temozolomide

Topics

• Antineoplastic Agents, Alkylating (pharmacology)
• Apoptosis (drug effects)
• Cell Adhesion (drug effects)
• Cell Cycle (drug effects)
• Cell Line, Tumor
• Cell Survival (drug effects)
• Dacarbazine (analogs & derivatives, pharmacology)
• Deferiprone
• Dose-Response Relationship, Drug
• Drug Synergism
• Glioma
• Humans
• Inhibitory Concentration 50
• Iron Chelating Agents (pharmacology)
• Pyridones (pharmacology)
• Temozolomide